<SEC-DOCUMENT>0001181431-13-053304.txt : 20131009
<SEC-HEADER>0001181431-13-053304.hdr.sgml : 20131009
<ACCEPTANCE-DATETIME>20131009160136
ACCESSION NUMBER:		0001181431-13-053304
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20131009
FILED AS OF DATE:		20131009
DATE AS OF CHANGE:		20131009

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE

	BUSINESS ADDRESS:	
		STREET 1:		9640 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9640 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Nadav Eran
		CENTRAL INDEX KEY:			0001587852

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		131143476

	MAIL ADDRESS:	
		STREET 1:		301 COMMERCE STREET
		STREET 2:		SUITE 3300
		CITY:			FORT WORTH
		STATE:			TX
		ZIP:			76102
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>rrd392555.xml
<DESCRIPTION>FORM 3
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2013-10-09</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001125345</issuerCik>
        <issuerName>MACROGENICS INC</issuerName>
        <issuerTradingSymbol>MGNX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001587852</rptOwnerCik>
            <rptOwnerName>Nadav Eran</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O TPG GLOBAL, LLC</rptOwnerStreet1>
            <rptOwnerStreet2>301 COMMERCE STREET, SUITE 3300</rptOwnerStreet2>
            <rptOwnerCity>FORT WORTH</rptOwnerCity>
            <rptOwnerState>TX</rptOwnerState>
            <rptOwnerZipCode>76102</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>No securities beneficially owned</value>
                <footnoteId id="F1"/>
                <footnoteId id="F2"/>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>0</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">Dr. Eran Nadav is a TPG Principal.  TPG is affiliated with TPG Biotechnology Partners, L.P. and TPG Ventures, L.P. (collectively, the &quot;TPG Funds&quot;), which collectively hold shares of Series B Preferred Stock, Series C Preferred Stock and Series D-2 Preferred Stock (collectively, the &quot;TPG Preferred Stock&quot;) of MacroGenics, Inc. (&quot;the Issuer&quot;) and warrants to purchase shares of Series D-2 Preferred Stock of the Issuer (the &quot;TPG Warrants&quot;), which are convertible or exercisable into an aggregate of 2,209,934 shares (the &quot;TPG Shares&quot; and, together with the TPG Preferred Stock and the TPG Warrants, the &quot;TPG Securities&quot;) of Common Stock, par value $0.01 per share, of the Issuer.</footnote>
        <footnote id="F2">Dr. Nadav disclaims beneficial ownership of all of the TPG Securities that are or may be beneficially owned by the TPG Funds or any of their affiliates.  Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the &quot;Exchange Act&quot;), this filing shall not be deemed an admission that Dr. Nadav is, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities of the Issuer for purposes of Section 16 of the Exchange Act or otherwise.</footnote>
    </footnotes>

    <remarks>Ronald Cami is signing on behalf of Dr. Nadav pursuant to the authorization and designation letter dated September 24, 2013, which is filed as an exhibit to this Form 3.</remarks>

    <ownerSignature>
        <signatureName>/s/ Ronald Cami on behalf of Eran Nadav</signatureName>
        <signatureDate>2013-10-09</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24.
<SEQUENCE>2
<FILENAME>rrd353160_399986.htm
<DESCRIPTION>AUTHORIZATION LETTER
<TEXT>
<HTML>
<HEAD>
<TITLE>
rrd353160_399986.html
</TITLE>
</HEAD>
<BODY>
<PRE>
TPG

                               September 24, 2013


Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549

        This letter confirms that Ronald Cami, John E. Viola and David Reintjes
are authorized and designated to sign all securities related filings with the
Securities and Exchange Commission, including Form ID Acknowledgements, on my
behalf. This authorization and designation shall be valid for three years from
the date of this letter.

                                        Very truly yours,

                                        /s/ Dr. Eran Nadav
                                        ---------------------------------------
                                        Dr. Eran Nadav
</PRE>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
